Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991-2000

Clinical Infectious Diseases

Volumn 38, Issue 3, 2004, Pages 311-320

  Marchetti, Oscar ^a   Bille, Jacques ^a   Fluckiger, Ursula ^b   Eggimann, Philippe ^c   Ruef, Christian ^c   Garbino, Jorge ^d   Calandra, Thierry ^a   Glauser, Michel Pierre ^a   Täuber, Martin George ^e   Pittet, Didier ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PYRROLE;

CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDIASIS; FUNGAL STRAIN; HEALTH SURVEY; HUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SWITZERLAND; UNIVERSITY; UNIVERSITY HOSPITAL;

ANTIFUNGAL AGENTS; CANDIDIASIS; CROSS INFECTION; DATA COLLECTION; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; FUNGEMIA; HOSPITALS, UNIVERSITY; HUMANS; LONGITUDINAL STUDIES; MICROBIAL SENSITIVITY TESTS; SWITZERLAND; UNITED STATES;

EID: 10744222717     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380637     Document Type: Review

References (31)

1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-5.
2. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-78.
3. Rentz AM, Halpern MT, Bowden RA. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-8.
4. Edmond MB, Wallace SE, McKlish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
5. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1990. Am J Med 1991; 91(Suppl 3B):86S-9S.
6. Beck-Sagué CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. The National Nosocomial Infection Surveillance System. J Infect Dis 1993; 167:1247-51.
7. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Arch Intern Med 1995; 155:1177-84.
8. Trick W, Fridkin S, Edwards JE, Hajjeh R, Gaynes R. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. The National Nosocomial Infections Surveillance System Hospitals. Clin Infect Dis 2002; 35:627-30.
9. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325:1274-7.
10. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-8.
11. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.
12. White MH. The contribution of fluconazole to the changing epidemiology of invasive candidal infections [editorial]. Clin Infect Dis 1997; 24:1129-30.
13. Voss A, Kluytmans JA, Koeleman JGM, et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996; 15:909-12.
14. Fluit AC, Jones ME, Schmitz F-J, et al. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin Infect Dis 2000; 30:454-60.
15. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998; 36:3455-9.
16. Warren N, Hazen K. Candida, Cryptococcus, and other yeasts of medical importance. In: Murray PR, ed. Manual of clinical microbiology. Washington, DC: ASM Press, 1999:1184-99.
17. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. Villanova, PA: NCCLS, 1997.
18. Chen YC, Chang SC, Sun CC, Yang LS, Hsieh WC, Luh KT. Secular trends in the epidemiology of nosocomial fungal infections at a teaching hospital in Taiwan, 1981 to 1993. Infect Control Hosp Epidemiol 1997; 18:369-75.
19. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002; 81:425-33.
20. Berrouane YF, Herwaldt L-A, Pfaller MA. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital. J Clin Microbiol 1999; 37:531-7.
21. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A. Candidemia in French hospitals: incidence rates and characteristics. The French Candidemia Study Group. Clin Microbiol Infect 2002; 8:405-12.
22. Tortorano AM, Biraghi E, Astolfi A, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51:297-304.
23. Rex JH, Walsh TJ, Sobel J, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
24. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40:3551-7.
25. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
26. St Germain G, Laverdiere M, Pelletier R, et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001; 39:949-53.
27. Pfaller MA, Jones RN, Doern G, et al. Bloodstream infection due to Candida species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44:747-51.
28. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001; 126:397-414.
29. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437-40.
30. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-72.
31. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-17.